Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Activating agent of stem cells and/or progenitor cells

A stem cell and progenitor cell technology, applied in the direction of non-embryonic pluripotent stem cells, cell culture support/coating, animal cells, etc., can solve problems such as the evaluation of batroxobin

Active Publication Date: 2008-10-01
TOBISHI PHARMA CO LTD
View PDF5 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, this report does not make any evaluation on the effect of batroxobin on stem cells and / or progenitor cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Activating agent of stem cells and/or progenitor cells
  • Activating agent of stem cells and/or progenitor cells
  • Activating agent of stem cells and/or progenitor cells

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0114] The activation effect of batroxobin on CD34 positive mononuclear cells derived from umbilical cord blood

[0115] In this example, the activation effect of batroxobin on CD34-positive mononuclear cells derived from umbilical cord blood was evaluated in vitro.

[0116] Furthermore, it is known that cells consistent with CD34-positive mononuclear cells present in umbilical cord blood consist of vascular EPCs and mesenchymal stem cells (Murohara T et al.: Transplanted cordblood-derived endothelial precursor cells augment postnatal neovascularization. J Clin Invest 105: 1527 -1536, 2000). Therefore, it can be said that the human umbilical cord blood-derived CD34-positive mononuclear cells evaluated in this example are vascular EPCs and mesenchymal stem cells.

[0117] experimental method:

[0118] (1) Collection of human umbilical cord blood mononuclear cells

[0119] Normal pregnancy with full-term delivery was selected, and 40-60 ml of umbilical cord blood was coll...

Embodiment 2

[0131] Activation of CD34-positive cells, CD34-positive / CD31-positive cells and vascular endothelial-cadherin-positive cells in peripheral blood of patients with deep venous thrombosis of lower extremities, and the function recovery effect of batroxobin on injured tissues in patients with deep venous thrombosis of lower extremities

[0132] In the present embodiment, batroxobin is used in patients suffering from a kind of vascular disease-lower extremity deep venous thrombosis (lower extremity DVT), to evaluate batroxobin on CD34 positive cells, CD34 positive / CD31 positive cells and The activating effect of VE-Cadherin positive cells, and the regenerative effect of batroxobin on thrombus-injured blood vessels.

[0133] In addition, those cells considered to be CD34-positive mononuclear cells present in peripheral blood are known to be vascular EPCs and mesenchymal stem cells (Zhao Y et al.: A human peripheral blood monocyte-derived subset acts as pleuripotent stem cells.Proc N...

Embodiment 3

[0186] Effect of batroxobin on neural stem cells and / or neural progenitor cells in cerebral ischemia / reperfusion injury model

[0187] The role of life and neurological recovery

[0188] In this example, the effect of batroxobin on the activation of neural stem cells and / or neural progenitor cells and the recovery of neural function was evaluated using a rat cerebral ischemia / reperfusion injury model.

[0189] experimental method:

[0190] (1) animal

[0191] Male Sprague-Dawley rats (Shanghai Animal Center, Chinese Academy of Medical Sciences, Shanghai, China) aged 12 weeks and weighing 250-280 g were used for the experiment after acclimatization for 1 week.

[0192] (2) Establishment of cerebral ischemia / reperfusion injury model

[0193] First, a middle cerebral artery occlusion model was established according to the method of Longa EZ et al. (Longa EZ et al.: Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20:84-91, 1...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
lengthaaaaaaaaaa
purityaaaaaaaaaa
Login to View More

Abstract

The present invention provides an activating agent of stem cells and / or progenitor cells comprising a thrombin-like enzyme which can be used in regenerative medicine, and particularly in regenerative medicine utilizing self-regeneration, acting promptly and moderately depending on the state of advancement and the degree of injured organs and / or tissues to which regenerative medicine is applied, with few or no side effects. The present invention also provides a method for activating stem cells and / or progenitor cells in an animal comprising the step of administering to the animal an effective amount of a thrombin-like enzyme and use of the thrombin-like enzyme for activating stem cells and / or progenitor cells.

Description

technical field [0001] The present invention relates to an agent for activating stem cells and / or progenitor cells comprising thrombin, and to a method for activating stem cells and / or progenitor cells in an animal comprising the step of administering an effective amount of thrombin to the animal, As well as the use of thrombin-like enzymes for activating stem cells and / or progenitor cells. Background technique [0002] Diseases that occur in humans can be roughly divided into organic diseases and functional diseases. In traditional medicine, medical treatment is mainly used for functional diseases, while surgical treatment and medical treatment are used for organic diseases. However, most medical treatments are symptomatic and in many cases cannot cure the disease. Furthermore, surgical treatment is an invasive method of treatment performed by removing all or part of the damaged organ, resulting in partial or complete loss of organ function. On the other hand, organ tran...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N9/64C12N5/06C12N5/074C12N5/0789C12N5/0797
CPCA61K38/00C12N9/6418C12N5/0623C12N5/0647C12N2533/56C12N5/0692A61P1/00A61P1/02A61P1/04A61P1/16A61P1/18A61P3/04A61P3/06A61P3/10A61P5/18A61P7/00A61P7/02A61P9/00A61P9/04A61P9/06A61P9/10A61P9/12A61P9/14A61P11/00A61P11/04A61P11/06A61P11/14A61P13/02A61P13/08A61P13/10A61P13/12A61P17/00A61P17/02A61P17/06A61P17/14A61P17/16A61P19/02A61P19/08A61P21/02A61P25/00A61P25/02A61P25/16A61P25/28A61P27/02A61P31/04A61P31/06A61P35/00A61P37/08A61P43/00C12N5/00C12N5/0602C12N9/64
Inventor 千贺博文韩忠朝蔡定芳栗力
Owner TOBISHI PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com